Overview

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Esomeprazole
Rabeprazole